Overview

Welcome to Stayble Therapeutics AB´s IR pages

Stayble Therapeutics is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. STA363 is intended for patients not improving after treatment with analgesics and physiotherapy.

LATEST PRESS RELEASES

31 July 2020 Regulatory

First patient treated in Stayble’s clinical phase 2b study

Stayble Therapeutics announces today, July 31, 2020, that the first patient has been treated in Stayble’s clinical phase 2b study. STA363 is targeting patients suffering from chronic low back pain c...

02 July 2020

Stayble’s clinical phase 2b study has now also started in the Netherlands

Stayble announces today, July 2, 2020, that the Company has initiated the first clinic in the Netherlands and now recruiting patients. The company has previously initiated clinics in Russia. STA363 is...

FINANCIAL CALENDAR

Interim report Q3 2020
16November2020
Interim report Q4 2020
15February2021